litlas
Log inCreate account

Neeraj Agarwal

Active 1988–2025

325
Papers
36,993
Citations
96
h-index
285
i10-index

Citations

Citations per year for Neeraj Agarwal1988: 1 citations1989: 2 citations1990: 4 citations1991: 8 citations1992: 15 citations1993: 24 citations1994: 20 citations1995: 15 citations1996: 15 citations1997: 12 citations1998: 19 citations1999: 17 citations2000: 15 citations2001: 26 citations2002: 24 citations2003: 22 citations2004: 41 citations2005: 27 citations2006: 36 citations2007: 45 citations2008: 50 citations2009: 57 citations2010: 74 citations2011: 54 citations2012: 54 citations2013: 89 citations2014: 96 citations2015: 123 citations2016: 178 citations2017: 208 citations2018: 238 citations2019: 775 citations2020: 1,354 citations2021: 1,961 citations2022: 1,494 citations2023: 1,289 citations2024: 2,356 citations2025: 1,184 citations2026: 45 citations

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 4,237 citing papers, 24.2% of this breakdownChina: 1,837 citing papers, 10.5% of this breakdownItaly: 1,069 citing papers, 6.1% of this breakdownUnited Kingdom: 1,045 citing papers, 6% of this breakdownGermany: 845 citing papers, 4.8% of this breakdownFrance: 791 citing papers, 4.5% of this breakdownCanada: 767 citing papers, 4.4% of this breakdownSpain: 654 citing papers, 3.7% of this breakdownJapan: 610 citing papers, 3.5% of this breakdownAustralia: 466 citing papers, 2.7% of this breakdownNetherlands: 380 citing papers, 2.2% of this breakdownSwitzerland: 359 citing papers, 2% of this breakdown
0%24.2%Other 25.4%

Institutions

Fields

  • Medicine73.7%
  • Biochemistry, Genetics and Molecular Biology18.2%
  • Immunology and Microbiology3.3%
  • Neuroscience1.4%
  • Computer Science0.7%
  • Engineering0.7%
  • Other2%

Topics

  • Prostate Cancer Treatment and Research6.3%
  • Cancer Immunotherapy and Biomarkers5.5%
  • Renal cell carcinoma treatment5.1%
  • Bladder and Urothelial Cancer Treatments4.7%
  • Prostate Cancer Diagnosis and Treatment3.4%
  • Cancer Genomics and Diagnostics2.6%
  • Other72.4%

Coauthors

All papers

Open in search
  1. Olaparib for Metastatic Castration-Resistant Prostate Cancer

    Authors: Johann S. de Bono, Joaquı́n Mateo, Karim Fizazi, Fred Saad, Neal D. Shore, Shahneen Sandhu, Kim N., Oliver Sartor, Neeraj Agarwal, David Olmos, Antoine Thiery-Vuillemin, Przemyslaw Twardowski, Niven Mehra, Carsten Goessl, Jinyu Kang, Joseph E. Burgents, Wenting Wu, Alexander Kohlmann, Carrie A. Adelman, Maha Hussain - New England Journal of Medicine 2020 cited by 2,237

  2. Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer

    Authors: Kim N., Neeraj Agarwal, Anders Bjartell, Byung Ha Chung, Andrea Juliana Gomes, Robert Given, Álvaro Juárez Soto, Axel S. Merseburger, Mustafa Özgüroğlu, Hirotsugu Uemura, Dingwei Ye, Kris Deprince, Vahid Naini, Jinhui Li, Shinta Cheng, Margaret K. Yu, Ke Zhang, Julie S. Larsen, Sharon McCarthy, Simon Chowdhury - New England Journal of Medicine 2019 cited by 1,513

  3. Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial

    Authors: Neeraj Agarwal, Arun Azad, Joan Carles, André P. Fay, Nobuaki Matsubara, Daniel Heinrich, Cezary Szczylik, Ugo De Giorgi, Jae Young Joung, Peter C.C. Fong, Éric Voog, Robert J. Jones, Neal D. Shore, Curtis Dunshee, Stefanie Zschäbitz, Jan Oldenburg, Xun Lin, Cynthia G. Healy, Nicola Di Santo, Fabian Zohren, Karim Fizazi - The Lancet 2023 cited by 499

  4. TROPHY-U-01: A Phase II Open-Label Study of Sacituzumab Govitecan in Patients With Metastatic Urothelial Carcinoma Progressing After Platinum-Based Chemotherapy and Checkpoint Inhibitors

    Authors: Scott T. Tagawa, Arjun Vasant Balar, Daniel P. Petrylak, Arash Rezazadeh Kalebasty, Yohann Loriot, Aude Fléchon, Rohit Jain, Neeraj Agarwal, Manojkumar Bupathi, Philippe Barthélémy, Philippe Beuzeboc, Phillip L. Palmbos, Christos E. Kyriakopoulos, Damien Pouessel, Cora N. Sternberg, Quan Hong, Trishna Goswami, Loretta M. Itri, Petros Grivas - Journal of Clinical Oncology 2021 cited by 533

  5. Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer

    Authors: Maha Hussain, Joaquı́n Mateo, Karim Fizazi, Fred Saad, Neal D. Shore, Shahneen Sandhu, Kim N., Oliver Sartor, Neeraj Agarwal, David Olmos, Antoine Thiery-Vuillemin, Przemyslaw Twardowski, Guilhem Roubaud, Mustafa Özgüroğlu, Jinyu Kang, Joseph E. Burgents, Christopher Gresty, Claire Corcoran, Carrie A. Adelman, Johann S. de Bono - New England Journal of Medicine 2020 cited by 766

  6. Advances in bladder cancer biology and therapy

    Authors: Linda L. Tran, Jin-Fen Xiao, Neeraj Agarwal, Jason E. Duex, Dan Theodorescu - Nature reviews. Cancer 2020 cited by 794

  7. Kidney Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology

    Authors: Robert J. Motzer, Eric Jonasch, Neeraj Agarwal, Ajjai Alva, Michael J. Baine, Kathryn E. Beckermann, Maria I. Carlo, Toni K. Choueiri, Brian A. Costello, Ithaar Derweesh, Arpita Desai, Yasser Ged, Saby George, John L. Gore, Naomi B. Haas, Steven Hancock, Payal Kapur, Christos E. Kyriakopoulos, Elaine T. Lam, Primo N. Lara, Clayton Lau, Bryan Lewis, David C. Madoff, Brandon J. Manley, M. Dror Michaelson, Amir Mortazavi, Lakshminarayanan Nandagopal, Elizabeth R. Plimack, Lee Ponsky, Sundhar Ramalingam, Brian Shuch, Zachary L. Smith, Jeffrey A. Sosman, Mary A. Dwyer, Lisa A. Gurski, Angela D. Motter - Journal of the National Comprehensive Cancer Network 2022 cited by 655

  8. Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial

    Authors: Eugene D. Kwon, Charles G. Drake, H. I. Scher, Karim Fizazi, Alberto Bossi, Alfons J.M. van den Eertwegh, Michael Krainer, Nadine Houédé, Ricardo Vieira Santos, Hakim Mahammedi, Siobhan Ng, Michele Maio, Fábio Franke, Santhanam Sundar, Neeraj Agarwal, Andries M. Bergman, Tudor–Eliade Ciuleanu, Ernesto Korbenfeld, Lisa Sengeløv, Steinbjørn Hansen, C. Logothetis, Tomasz M. Beer, M. Brent McHenry, Paul Gagnier, David Liu, Winald R. Gerritsen - The Lancet Oncology 2014 cited by 1,496

  9. Apalutamide in Patients With Metastatic Castration-Sensitive Prostate Cancer: Final Survival Analysis of the Randomized, Double-Blind, Phase III TITAN Study

    Authors: Kim N., Simon Chowdhury, Anders Bjartell, Byung Ha Chung, Andrea Juliana Gomes, Robert Given, Álvaro Juárez, Axel S. Merseburger, Mustafa Özgüroğlu, Hirotsugu Uemura, Dingwei Ye, Sabine Brookman‐May, Suneel Mundle, Sharon McCarthy, Julie S. Larsen, Weili Sun, Katherine B. Bevans, Ke Zhang, Nibedita Bandyopadhyay, Neeraj Agarwal - Journal of Clinical Oncology 2021 cited by 508

  10. NCCN Guidelines® Insights: Bladder Cancer, Version 2.2022

    Authors: Thomas W. Flaig, Philippe E. Spiess, Michael Abern, Neeraj Agarwal, Rick Bangs, Stephen A. Boorjian, Mark K. Buyyounouski, Kevin Chan, Sam S. Chang, Terence W. Friedlander, Richard E. Greenberg, Khurshid A. Guru, Harry W. Herr, Jean Hoffman‐Censits, Amar U. Kishan, Shilajit Kundu, Subodh M. Lele, Ronac Mamtani, Vitaly Margulis, Omar Y. Mian, Jeff M. Michalski, Jeffrey S. Montgomery, Lakshminarayanan Nandagopal, Lance C. Pagliaro, Mamta Parikh, Anthony Patterson, Elizabeth R. Plimack, Kamal S. Pohar, Mark A. Preston, Kyle A. Richards, Wade J. Sexton, Arlene O. Siefker‐Radtke, Matthew K. Tollefson, Jonathan D. Tward, Jonathan L. Wright, Mary A. Dwyer, Carly J. Cassara, Lisa A. Gurski - Journal of the National Comprehensive Cancer Network 2022 cited by 302

  11. CD70-Targeted Allogeneic CAR T-Cell Therapy for Advanced Clear Cell Renal Cell Carcinoma

    Authors: Sumanta K. Pal, Ben Tran, John B.A.G. Haanen, Michael E. Hurwitz, Adrian G. Sacher, Nizar M. Tannir, Lihua E. Budde, Simon J. Harrison, Sebastian Klobuch, Sagar S. Patel, Luís Meza, Mary‐Lee Dequéant, Anna Ma, Qiuling Ally He, Leah M. Williams, Alissa Keegan, Ellen B. Gurary, Henia Dar, Sushant Karnik, Changan Guo, Heidi Heath, Rachel R. Yuen, Phuong K. Morrow, Neeraj Agarwal, Samer A. Srour - Cancer Discovery 2024 cited by 139

  12. First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial

    Authors: Karim Fizazi, Arun Azad, Nobuaki Matsubara, Joan Carles, André P. Fay, Ugo De Giorgi, Jae Young Joung, Peter C.C. Fong, Éric Voog, Robert J. Jones, Neal D. Shore, Curtis Dunshee, Stefanie Zschäbitz, Jan Oldenburg, Dingwei Ye, Xun Lin, Cynthia G. Healy, Nicola Di Santo, Alexander Laird, Fabian Zohren, Neeraj Agarwal - Nature Medicine 2023 cited by 127

  13. Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial

    Authors: Toni K. Choueiri, Bernard Escudier, Thomas Powles, Nizar M. Tannir, Paul N. Mainwaring, Brian I. Rini, Hans J. Hammers, Frede Donskov, Bruce J. Roth, Katriina Peltola, Jae‐Lyun Lee, Daniel Y.C. Heng, Manuela Schmidinger, Neeraj Agarwal, Cora N. Sternberg, David F. McDermott, Dana T. Aftab, Colin Hessel, Christian Scheffold, Gisela Schwab, Thomas E. Hutson, Sumanta K. Pal, Robert J. Motzer - The Lancet Oncology 2016 cited by 939

  14. Efficacy and Safety of Telaglenastat Plus Cabozantinib vs Placebo Plus Cabozantinib in Patients With Advanced Renal Cell Carcinoma

    Authors: Nizar M. Tannir, Neeraj Agarwal, Camillo Porta, Nicola Jane Lawrence, Robert J. Motzer, Bradley A. McGregor, Richard J. Lee, Rohit Jain, Nancy B. Davis, Leonard J. Appleman, Oscar Goodman, Walter M. Stadler, Sunil Gandhi, Daniel M. Geynisman, Roberto Iacovelli, Begoña Mellado, Juan Manuel Sepúlveda-Sánchez, Robert A. Figlin, Thomas Powles, Lalith Akella, Keith Orford, Bernard Escudier - JAMA Oncology 2022 cited by 142

  15. Bladder Cancer, Version 1.2026, NCCN Clinical Practice Guidelines In Oncology

    Authors: Thomas W. Flaig, Philippe E. Spiess, Neeraj Agarwal, Rick Bangs, Stephen A. Boorjian, Mark K. Buyyounouski, Sam S. Chang, Tracy M. Downs, Jason A. Efstathiou, Terence W. Friedlander, Richard E. Greenberg, Khurshid A. Guru, Thomas Guzzo, Harry W. Herr, Jean Hoffman‐Censits, Christopher Hoimes, Brant A. Inman, Masahito Jimbo, A. Karim Kader, Subodh M. Lele, Jeff M. Michalski, Jeffrey S. Montgomery, Lakshminarayanan Nandagopal, Lance C. Pagliaro, Sumanta K. Pal, Anthony Patterson, Elizabeth R. Plimack, Kamal S. Pohar, Mark A. Preston, Wade J. Sexton, Arlene O. Siefker‐Radtke, Jonathan D. Tward, Jonathan L. Wright, Lisa A. Gurski, Alyse Johnson-Chilla - Journal of the National Comprehensive Cancer Network 2020 cited by 628

  16. External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study

    Authors: Daniel Y.C. Heng, Wanling Xie, Meredith M. Regan, Lauren C. Harshman, Georg A. Bjarnason, Ulka N. Vaishampayan, Mary J. MacKenzie, Lori Wood, Frede Donskov, Min-Han Tan, Sun Young Rha, Neeraj Agarwal, Christian Kollmannsberger, Brian I. Rini, Toni K. Choueiri - The Lancet Oncology 2013 cited by 1,029

  17. Deep, rapid, and durable prostate-specific antigen decline with apalutamide plus androgen deprivation therapy is associated with longer survival and improved clinical outcomes in TITAN patients with metastatic castration-sensitive prostate cancer

    Authors: S. Chowdhury, Anders Bjartell, Neeraj Agarwal, Byung Ha Chung, Robert Given, Andrea Juliana Gomes, Axel S. Merseburger, Mustafa Özgüroğlu, Álvaro Juárez Soto, Hirotsugu Uemura, D. Ye, Sabine Brookman‐May, Anil Londhe, Amitabha Bhaumik, Suneel Mundle, Julie S. Larsen, Sharon McCarthy, K.N. Chi - Annals of Oncology 2023 cited by 113

  18. Enhancing Triage Efficiency and Accuracy in Emergency Rooms for Patients with Metastatic Prostate Cancer: A Retrospective Analysis of Artificial Intelligence-Assisted Triage Using ChatGPT 4.0

    Authors: Georges Gebrael, Kamal Kant Sahu, Beverly Chigarira, Nishita Tripathi, Vinay Mathew Thomas, Nicolas Sayegh, Benjamin L. Maughan, Neeraj Agarwal, Umang Swami, Haoran Li - Cancers 2023 cited by 85

  19. CDK12-Altered Prostate Cancer: Clinical Features and Therapeutic Outcomes to Standard Systemic Therapies, Poly (ADP-Ribose) Polymerase Inhibitors, and PD-1 Inhibitors

    Authors: Emmanuel S. Antonarakis, Pedro Isaacsson Velho, Wei Fu, Hao Wang, Neeraj Agarwal, Víctor Sacristán Santos, Benjamin L. Maughan, Роберто Пили, Nabil Adra, Cora N. Sternberg, Panagiotis J. Vlachostergios, Scott T. Tagawa, Alan H. Bryce, Andrea McNatty, Zachery R. Reichert, Robert Dreicer, Oliver Sartor, Tamara L. Lotan, Maha Hussain - JCO Precision Oncology 2020 cited by 206

  20. Advanced Prostate Cancer: Treatment Advances and Future Directions

    Authors: Umang Swami, Taylor Ryan McFarland, Roberto Nussenzveig, Neeraj Agarwal - Trends in cancer 2020 cited by 248

  21. Olaparib for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer and Alterations in BRCA1 and/or BRCA2 in the PROfound Trial

    Authors: Joaquı́n Mateo, Johann S. de Bono, Karim Fizazi, Fred Saad, Neal D. Shore, Shahneen Sandhu, Kim N., Neeraj Agarwal, David Olmos, Antoine Thiery-Vuillemin, Mustafa Özgüroğlu, Niven Mehra, Nobuaki Matsubara, Jae Young Joung, Charles Padua, Ernesto Korbenfeld, Jinyu Kang, Helen Marshall, Zhongwu Lai, Alan Barnicle, Christian Poehlein, Natalia Lukashchuk, Maha Hussain - Journal of Clinical Oncology 2023 cited by 91

  22. Phase III Trial of PROSTVAC in Asymptomatic or Minimally Symptomatic Metastatic Castration-Resistant Prostate Cancer

    Authors: James L. Gulley, Michael Borre, Nicholas J. Vogelzang, Siobhan Ng, Neeraj Agarwal, Chris Parker, David Pook, Per Rathenborg, Thomas W. Flaig, Joan Carles, Fred Saad, Neal D. Shore, Liddy Chen, Christopher R. Heery, Winald R. Gerritsen, Frank Priou, Niels Christian Langkilde, A I Novikov, Philip W. Kantoff - Journal of Clinical Oncology 2019 cited by 278

  23. Bladder Cancer, Version 3.2024

    Authors: Thomas W. Flaig, Philippe E. Spiess, Michael Abern, Neeraj Agarwal, Rick Bangs, Mark K. Buyyounouski, Kevin Chan, Sam S. Chang, Paul Chang, Terence W. Friedlander, Richard E. Greenberg, Khurshid A. Guru, Harry W. Herr, Jean Hoffman‐Censits, Hristos Z. Kaimakliotis, Amar U. Kishan, Shilajit Kundu, Subodh M. Lele, Ronac Mamtani, Omar Y. Mian, Jeff M. Michalski, Jeffrey S. Montgomery, Mamta Parikh, Anthony Patterson, Charles C. Peyton, Elizabeth R. Plimack, Mark A. Preston, Kyle A. Richards, Wade J. Sexton, Arlene O. Siefker‐Radtke, Tyler F. Stewart, Debasish Sundi, Matthew K. Tollefson, Jonathan D. Tward, Jonathan L. Wright, Carly J. Cassara, Lisa A. Gurski - Journal of the National Comprehensive Cancer Network 2024 cited by 236

  24. Final Analysis of the Ipilimumab Versus Placebo Following Radiotherapy Phase III Trial in Postdocetaxel Metastatic Castration-resistant Prostate Cancer Identifies an Excess of Long-term Survivors

    Authors: Karim Fizazi, Charles G. Drake, Tomasz M. Beer, Eugene D. Kwon, Howard I. Scher, Winald R. Gerritsen, Alberto Bossi, Alfons J.M. van den Eertwegh, Michael Krainer, Nadine Houédé, Ricardo Vieira Santos, Hakim Mahammedi, Siobhan Ng, Riccardo Danielli, Fábio Franke, Santhanam Sundar, Neeraj Agarwal, Andries M. Bergman, Tudor–Eliade Ciuleanu, Ernesto Korbenfeld, Lisa Sengeløv, Steinbjørn Hansen, M. Brent McHenry, Allen Chen, Christopher J. Logothetis - European Urology 2020 cited by 175